Results 51 to 60 of about 11,994 (242)

Higher clearance of micafungin in neonates compared with adults: role of age‐dependent micafungin serum binding [PDF]

Biopharmaceutics & Drug Disposition, 2011
AbstractMicafungin, a new echinocandin antifungal agent, has been used widely for the treatment of various fungal infections in human populations. Micafungin is predominantly cleared by biliary excretion and it binds extensively to plasma proteins.
Souzan B. Yanni, P. Brian Smith, Daniel K. Benjamin, Patrick Augustijns, Dhiren R. Thakker, Pieter Annaert   +5 more
openalex   +5 more sources

PHARMACOECONOMIC ANALYSIS OF MICAFUNGIN USING IN THE TREATMENT OF INVASIVE CANDIDIASIS IN NEWBORNS

Педиатрическая фармакология, 2011
Invasive candidiasis is a common cause of neonatal sepsis, especially in children with very low birth weight. This study, for the first time in the world of medical research, shows the results of the clinico-economical expertise of using micafungin to ...
A.S. Kolbin, M.A. Proskurin, Yu.A. Balykina, N.N. Klimko   +3 more
doaj   +2 more sources

Susceptibility of the Candida haemulonii Complex to Echinocandins: Focus on Both Planktonic and Biofilm Life Styles and a Literature Review

Journal of Fungi, 2020
Candida haemulonii complex (C. haemulonii, C. duobushaemulonii and C. haemulonii var. vulnera) is well-known for its resistance profile to different available antifungal drugs.
Lívia S. Ramos, Laura N. Silva, Marta H. Branquinha, André L. S. Santos   +3 more
doaj   +1 more source

ESCMID‐EFISG Survey on Diagnostic and Therapeutic Capacity for Invasive Fungal Infections in Belgium, the Netherlands, and Luxembourg: A Focus on High Azole Resistance

Mycoses, Volume 68, Issue 7, July 2025.
ABSTRACT Introduction Invasive fungal infections (IFI) are a major clinical challenge, particularly in immunocompromised patients, and are associated with high morbidity and mortality. With the increasing prevalence of immunosuppressive conditions and ageing populations, the incidence of IFI is rising globally.
Robina Aerts, Lize Cuypers, Eelco F. J. Meijer, Michel Kohnen, Jacques F. Meis, Oliver A. Cornely, Katrien Lagrou, Jon Salmanton‐García, Alex Wagemakers, Stefan Vestjens, Peter Verbeeck, Geert Vanheule, Marc Vandevelde, Jens van Van Praet, Bruno van Van Herendael, Jaap van Doesum, Karin van Van Dijk, Alieke van der Van der Hoeven, Wendy W. J. van de Van de Sande, Marijke Reynders, Ann Packeu, Yarah Overmeire, Claudy Oliveira‐dos‐Santos, Eric Nulens, Alexandre Mzabi, Astrid Muyldermans, Isabel Montesinos, Willem Melchers, Johan Maertens, Karel Maelegheer, Sybren Lekkerkerk, Nathalie Layios, Eva Kolwijck, Stijn Jonckheere, Louis Ide, Marie‐Pierre Hayette, Ferry Hagen, Pieter‐Jan Haas, Truus Goegebuer, Peggy Godschalk, Anne‐Isabelle de Moreau, Emmanuel de Laere, Julien de Greef, Deborah de Geyter, Peter Croughs, Philippe Clevenbergh, Jolien Claessens, Ga‐Lai Chong, Reinoud Cartuyvels, Jochem Buil, Roger Bruggemann, Jerina Boelens, An Boel, Robbert Bentvelsen   +53 more
wiley   +1 more source

Update of the list of qualified presumption of safety (QPS) recommended microbiological agents intentionally added to food or feed as notified to EFSA 22: Suitability of taxonomic units notified to EFSA until March 2025

EFSA Journal, Volume 23, Issue 7, July 2025.
Abstract The qualified presumption of safety (QPS) process was developed to assess the safety of microorganisms used in food and feed chains. During the period covered by this Statement, no new information warranted changes to the status of previously recommended QPS taxonomic units.
EFSA Panel on Biological Hazards (BIOHAZ), Ana Allende, Avelino Alvarez‐Ordóñez, Valeria Bortolaia, Sara Bover‐Cid, Alessandra De Cesare, Wietske Dohmen, Laurent Guillier, Liesbeth Jacxsens, Maarten Nauta, Lapo Mughini‐Gras, Jakob Ottoson, Luisa Peixe, Fernando Perez‐Rodriguez, Panagiotis Skandamis, Elisabetta Suffredini, Pier Sandro Cocconcelli, Pablo Salvador Fernández Escámez, Miguel Prieto Maradona, Amparo Querol, Lolke Sijtsma, Juan Evaristo Suarez, Marianne Chemaly, Ingvar Sundh, Fulvio Barizzone, Justine Dastouet, Nadya Doyle, Sandra Correia, Lieve Herman   +28 more
wiley   +1 more source

COMPARISON OF THREE DISTINCT PROPHYLACTIC AGENTS AGAINST INVASIVE FUNGAL INFECTIONS IN PATIENTS UNDERGOING HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION AND POST-TRANSPLANT CYCLOPHOSPHAMIDE

Mediterranean Journal of Hematology and Infectious Diseases, 2015
Over the past decade, invasive fungal infections (IFI) have remained an important problem in patients undergoing allogeneic haematopoietic stem cell transplantation (Allo-HSCT).
Jean Elcheikh
doaj   +1 more source

Clinical and pathological features of two cases of erythematous‐ceruminous otitis externa associated with Candida spp. infection in dogs

Veterinary Record Case Reports, Volume 13, Issue 2, June 2025.
Abstract Erythematous‐ceruminous otitis externa is a common presentation of otitis externa in dogs and is usually associated with Malassezia or bacterial overgrowth. This report aims to describe two cases of unilateral erythematous‐ceruminous otitis externa associated with Candida spp. infection. A 2‐year‐old goldendoodle (Case 1) and a 4‐year‐old Jack
Nuria García, Marina García, Lluís Ferrer, Laura Ordeix   +3 more
wiley   +1 more source

Pooled analysis of safety for micafungin [PDF]

Critical Care, 2008
Micafungin (MICA) is an efficacious antifungal treatment for life-threatening fungal infections [1-4].
P Maddison, Oliver A. Cornely, Andrew J. Ullmann   +2 more
openaire   +2 more sources

Approaches to Invasive Fungal Diseases in Paediatric Cancer Centres: An Analysis of Current Practices and Challenges in Germany, Austria and Switzerland

Mycoses, Volume 68, Issue 6, June 2025.
ABSTRACT Background Invasive fungal diseases (IFD) pose significant challenges in paediatric oncology. Their management is complicated by limited paediatric‐specific evidence, lack of standardised protocols and variability in resources across centres.
Danila Seidel, Zoi Dorothea Pana, Daniel Ebrahimi‐Fakhari, Sarina K. Butzer, Katrin Mehler, Ilana Reinhold, Arne Simon, Christian Dohna‐Schwake, Ines Mack, Nicole Bodmer, Tim Niehues, Alexander Claviez, Alfred Längler, Alfred Leipold, Aram Prokop, Bastian Brummel, Beate Winkler, Bernd Gruhn, Carl Friedrich Classen, Carsten Friedrich, Christa Koenig, Christian Flotho, Fiona Poyer, Freimut Schilling, Gabriele Calaminus, Geeke Sieben, Georg C. Schwabe, Harald Reinhard, Heiko‐Manuel Teltschik, Heinz Hengartner, Jana Stursberg, Jeanette Greiner, Johann Greil, Jörg Leyh, Jörn‐Sven Kühl, Karoline Ehlert, Konrad Bochennek, Marius Rohde, Martin Demmert, Martina Stiefel, Matthias Eyrich, Meinolf Siepermann, Michael Frühwald, Michaela Döring, Michaela Nathrath, Milen Minkov, Monika Streiter, Neil Jones, Nora Naumann‐Bartsch, Norbert Jorch, Olaf Beck, Rita Beier, Roman Crazzolara, Silke Kietz, Simon Vieth, Stefan Fröhling, Stephan Lobitz, Sujal Ghosh, Tanja C. Vallée, Thilo Müller, Thomas Wiesel, Tobias Däbritz, Udo Kontny, Uwe Thiel, Volker Strenger, Wolfgang R. Eberl, Oliver A. Cornely, Andreas H. Groll, Thomas Lehrnbecher   +68 more
wiley   +1 more source

Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species

Journal of Fungi, 2020
Rezafungin is a next-generation echinocandin that has favorable pharmacokinetic properties. We compared the occurrence of paradoxical growth (PG) and trailing effect (TE) characteristics to echinocadins with rezafungin, caspofungin, micafungin and ...
Zoltán Tóth, Lajos Forgács, Tamás Kardos, R. Kovács, J. B. Locke, G. Kardos, F. Nagy, A. Borman, A. Adnan, L. Majoros   +9 more
semanticscholar   +1 more source